MustGrow Biologics posts $0.8M in Q3 revenue as NexusBioAg drives margin growth

MustGrow Biologics Corp Chief Executive Officer Corey Giasson joined Steve Darling from Proactive to discuss the company’s financial results for the three months ended September 30, 2025, highlighting a meaningful step forward in revenue generation and margin performance. During the quarter, MustGrow reported revenue of $0.8 million, marking a significant improvement from the same period last year, when the company recorded no revenue. Gross profit for the quarter totaled $180,555, resulting in a gross margin of 22.9%, up from 20.9% in the second quarter of 2025. Giasson attributed the sequential improvement in margins to a stronger mix of higher-margin product sales through the company’s Canadian sales and distribution division, NexusBioAg. From a balance sheet perspective, MustGrow ended the quarter with $3.3 million in cash and cash equivalents, along with $1.9 million in inventory on hand. Giasson noted that the company remains disciplined in its capital allocation strategy, continuing to focus on investments that support revenue growth across both its NexusBioAg Canadian operations and its TerraSante biofertility product sales in the United States. Giasson also emphasized the seasonal nature of the company’s business, pointing out that the third calendar quarter is typically the lowest revenue “shoulder season” for Canadian agriculture, as farmers are more focused on harvesting activities rather than purchasing crop input products. Despite this seasonal slowdown, he said the company continues to make progress in strengthening its commercial platform and positioning itself for improved sales performance in future quarters. #proactiveinvestors #mustgrowbiologicscorp #tsxv #mgro #otcqb #mgrof #mustardseed #TerraSante #Biofertility #Agriculture #BiologicalFarming #RegenerativeAg #SustainableFarming #NexusBioAg #AgTech #CropProtection #FarmingInnovation #CanadianFarming #adjuvantsplus